Infect Dis Clin N Am 19 (2005) 563 568 Index Note: Page numbers of article titles are in boldface type. A Abstinence in genital herpes management, 436 Abuse sexual childhood sexual behavior effects of, 306 307 Antiviral therapy in genital herpes management, 436 437 Attitude(s) sexual behavior effects of, 304 305 B Bacterial STDs prevention and control of innovative approaches to, 513 540. See also Sexually transmitted diseases (STDs), bacterial, prevention and control of, innovative approaches to. Bacterial vaginosis, 393 401. See also Vaginosis, bacterial. Behavior(s) sexual. See Sexual behavior. Behavioral interventions and control, 514 520 C Cancer cervical screening for, 447 452 CDC. See Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC), 352 Cervical cancer screening for, 447 452 Cervical HPV infection oncogenic, 439 458. See also Human papillomavirus (HPV) infection, cervical. Cervicitis mucopurulent, 333 349. See also Mucopurulent cervicitis (MPC). Cervix anatomy and physiology of, 333 335 Chlamydia trachomatis detection of new specimen types for, 371 372 vaccines for, 478 Chlamydial infection clinical overview of, 283 epidemiology of, 283 288 assessment of challenges to, 283 in special populations estimates of, 285 286 microbiology of, 283 nucleic acid amplification tests for, 368 375. See also Nucleic acid amplification tests, for chlamydia. prevalence of population-based estimates of, 283 285 reported cases of, 287 screening for in males in bacterial STDs prevention and control, 522 surveillance for, 287 symptoms of, 287 Cluster tracing and control, 524, 527 Condom(s) in genital herpes management, 436 0891-5520/05/$ - see front matter Ó 2005 Elsevier Inc. All rights reserved. doi:10.1016/s0891-5520(05)00058-9 id.theclinics.com
564 INDEX Counseling for patients with genital HPV infection, 467 472. See also Genital HPV infection, counseling for patients with. for patients with genital HSV infection, 459 476. See also Genital HSV infection, counseling for patients with. risk-reduction in STD management in MCOs, Culture(s) for gonorrhea, 376 D Demography sexual behavior effects of, 300 305 Direct smear examination for gonorrhea, 375 376 E Expectation(s) sexual behavior effects of, 304 305 F Fluoroquinolone(s) mechanisms of action of, 354 357 Neisseria gonorrhoeae resistant to, 351 365. See also Neisseria gonorrhoeae, fluoroquinolone-resistant. G Genital HPV infection counseling for patients with, 467 472 external genital warts and, 472 key messages in, 470 471 partners and, 472 pregnancy-related, 472 special considerations in, 471 472 described, 467 educational challenge of, 469 470 psychosocial aspects of, 467 469 Genital HSV infection. See also Herpes simplex virus (HSV) infection, genital. counseling for patients with, 459 467 Genital warts external in genital HPV infection counseling for patients with, 472 GISP. See Gonococcal Isolate Surveillance Project (GISP). Gonococcal Isolate Surveillance Project (GISP), 352 Gonorrhea clinical overview of, 288 epidemiology of, 288 290 in special populations estimates of, 289 microbiology of, 288 nucleic acid amplification tests for, 375 379. See also Nucleic acid amplification tests, for gonorrhea. prevalence of population-based estimates of, 288 reported cases of, 289 290 surveillance for, 289 290 H Herpes simplex virus (HSV) infection barriers to dialogue about, 460 461 genital counseling for patients with, 459 476 asymptomatic shedding in, 466 determination of length of infection in, 465 466 importance of, 466 467 in asymptomatic patients who test positive, 466 psychosocial adjustment and, 463 465 described, 427 428, 459 460 diagnosis of disclosure of, 435 436 diagnostic tests for characteristics of, 430 damaging effects of, 434 during pregnancy, 433 434 in general population, 434 in high-risk patients, 432 433 in partners, 432 reliability of, 430 431 serologic assays, 430 432 identification of, 429 management of, 427 438 antiviral therapy in, 436 437 condoms in, 436 selective abstinence in, 436 medical importance of, 428 problems associated with, 428 429
transmission of management of, 435 talking with patients about, 461 463 vaccines for, 482 485 Herpes simplex virus (HSV) infection type 2 in HIV acquisition, 417 419 Herpes simplex virus (HSV) type 2 in HIV prevention, 421 422 in HIV spread, 417 in HIV transmission, 419 in outcomes of intervention trials for STDs, 419 421 treatment of impact on HIV progression, 422 423 Hierarchy sexual behavior effects of, 305 Homosexual men STDs in in Western Europe and U.S., 311 331. See also Sexually transmitted diseases (STDs), in homosexual men, in Western Europe and U.S. HPV infection. See Human papillomavirus (HPV) infection. HSV infection. See Herpes simplex virus (HSV) infection. Human immunodeficiency virus (HIV) infection acquisition of HSV type 2 in, 417 419 prevention of HSV type 2 in, 421 422 progression of HSV type 2 treatment impact on, 422 423 spread of HSV type 2 in, 417 transmission of HSV type 2 in, 419 Human immunodeficiency virus (HIV)/STDs interactions developments in, 415 425 Human papillomavirus (HPV) infection cervical epidemiology of, 439 447 natural history of, 439 447 oncogenic, 439 458 screening for, 447 452 diagnostic tests for, 452 453 vaccines for, 479 482 Hybridization INDEX probe for gonorrhea, 376 565 I Infection(s). See also specific types. sexually acquired in women Mycoplasma genitalium as, 407 408 Internet-based interventions and control, 532 M Managed care organizations (MCOs) STD care in, 491 511. See also Sexually transmitted diseases (STDs), treatment of, in MCOs. types of, 492 Mass treatment and control, 529 532 Mental health sexual behavior effects of, 306 307 Microbicide(s) and control, 520 521 MPC. See Mucopurulent cervicitis (MPC). Mucopurulent cervicitis (MPC), 333 349 causes of, 337 340 controversy related to, 344 defined, 335 337 epidemiology of, 335 337 management of, 342 344 future efforts related to, 344 nonchlamydial nongonococcal, 340 342 Mycoplasma genitalium as sexually acquired infection in women, 407 408 PID due to, 407 413. See also Pelvic inflammatory disease (PID), causes of. N Neisseria gonorrhoeae fluoroquinolone-resistant, 351 365. See also Fluoroquinolone(s). clinical significance of, 357 360 determinant mechanisms in, 354 357 epidemiology of, 357 360
566 INDEX Neisseria gonorrhoeae (continued ) future directions in, 360 361 prevalence of, 351 353 treatment of principles in, 353 354 nucleic acid amplification tests for, 375 vaccines for, 478 479 Nucleic acid amplification tests development of, 367 368 for chlamydia, 368 375 confirmation of positive tests, 372 epidemiologic effects of, 373 375 future of, 378 379 inhibitors of, 369 370 PCR, 368 professional organizations recommendations, 373 strand displacement amplification, 368 transcription mediated amplification, 368 369 for gonorrhea, 375 379 cost-effectiveness studies in, 377 cultures, 376 diagnostic specimen pooling in cost savings due to, 377 378 direct smear examination, 375 376 future of, 378 379 partnering in, 378 pelvic examination in, 377 probe hybridization, 376 sample of, 376 377 P Parental notification laws behavioral interventions for STDs and challenges to, 557 Partner therapy expedited and control, 527 529 Patient education in STD management in MCOs, PCR. See Polymerase chain reaction (PCR). Peer referral and control, 524, 527 Pelvic examination in gonorrhea detection, 377 Pelvic inflammatory disease (PID) causes of, 407 413 Mycoplasma genitalium, 407 413 described, 408 410 management of, 410 411 PID. See Pelvic inflammatory disease (PID). Polymerase chain reaction (PCR) for chlamydia, 368 Pregnancy genital HPV infection during, 472 genital HSV infection during diagnostic tests for, 433 434 Probe hybridization for gonorrhea, 376 Project RESPECT, 548 550 Q Quality of care of STDs in MCOs, 495 R Risk-reduction counseling in STD management in MCOs, S Selective mass treatment and control, 529 532 Sexual abuse childhood sexual behavior effects of, 306 307 Sexual behavior changes in attitudes effects on, 304 305 changes in expectations effects on, 304 305 changes in structure of marriage and family effects on, 304 changes in values effects on, 304 305 childhood sexual abuse effects on, 306 307 demographic effects on, 300 305 global socio-political and economic structure effects on, 299 300 hierarchy effects on, 305 mental health effects on, 306 307 modern day influences on, 297 309 technology effects on, 305 306 Sexually acquired infections in women Mycoplasma genitalium as, 407 408
INDEX 567 Sexually transmitted diseases (STDs) bacterial prevention and control of innovative approaches to, 513 540 behavioral interventions, 514 520 case-finding and treatmentrelated, 521 532 cluster tracing, 524, 527 expedited partner therapy, 527 529 female screening in medical care settings, 521 in unconventional locations, 522 523 Internet-based interventions, 532 male chlamydial screening, 522 mass treatment, 529 532 microbicides, 520 521 peer referral, 524, 527 rescreening, 523 524 behavioral interventions for, 541 562 behavioral models in, 545 548 case studies, 551 556 challenges of, 556 557 development of challenges in, 542 543 large-scale intervention studies, 550 551 objectives of, 548 parental notification laws related to challenges to, 557 problems associated with, 556 557 Project RESPECT, 548 550 sexual context impact on, 545 syphilis elimination, 552 Thai 100% Condom Program, 554 556 Uganda ABC Program, 553 554 health transition related to, 298 in homosexual men in Western Europe and U.S. epidemiology of changes in, 312 315 increase in, 311 331 biologic factors in, 315 317 demographic trends and, 317 high-risk sexual behavior and, 317 320 psychosocial contexts and, 322 325 reasons for, 315 325 sexual marketplace and, 320 322 intervention trials for outcomes of HSV type 2 in, 419 421 prevalence of, 491 492 risk factors for assessment bias in, 543 545 sexual behavior and, 297 309. See also Sexual behavior. treatment of in MCOs, 491 511 case reporting in, 503 504 clinical practice guidelines in, 494 495 described, 493 494 diagnostic testing in, 498 501 literature review methods in, 493 management of exposed sex partners, 504 505 patient education in, quality of care, 495 risk assessment in, 495 497 risk-reduction counseling in, screening in, 498 501 study of, 493 506 discussion of, 505 506 results of, 493 505 types of, 501 502 vaccines for acceptability of, 485 Chlamydia trachomatis, 478 future directions in, 485 486 HSV, 482 485 human papillomavirus, 479 482 Neisseria gonorrhoeae, 478 479 progress in, 477 490 Sexually transmitted diseases (STDs)/HIV interactions developments in, 415 425 Stages of Change Theory, 547 STDs. See Sexually transmitted diseases (STDs).
568 INDEX Strand displacement amplification for chlamydia, 368 Syphilis elimination of behavioral interventions for, 552 T Thai 100% Condom Program, 554 556 Theory of Reasoned Action, 548 549 Transcription mediated amplification for chlamydia, 368 369 Trichomoniasis, 387 393 clinical manifestations of, 388 390 clinical overview of, 290 complications of, 388 390 diagnosis of, 390 392 epidemiology of, 290 291, 387 388 in special populations estimates of, 291 microbiology of, 290 prevalence of population-based estimates of, 291 treatment of, 392 393 2001 Bethesda System, 444 445 U Uganda Abstinence/Be Faithful/Use Condoms (Uganda ABC Program), 553 554 V Vaccine(s) for STDs, 477 490. See also Sexually transmitted diseases (STDs), vaccines for. Vaginosis bacterial, 393 401 complications of, 396 399 diagnosis of, 399 400 epidemiology of, 393 pathophysiology of, 393 396 treatment of, 400 401 Value(s) sexual behavior effects of, 304 305 W Wart(s) genital external in genital HPV infection counseling for patients with, 472